bluebird bio, Inc. (BLUE) operates as a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
In August, BLUE announced the U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO, also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in patients who require regular red blood cell (RBC) transfusions.
